Claims for Patent: 9,217,147

Summary for Patent: 9,217,147

Title:	Spinal muscular atrophy treatment via targeting SMN2 catalytic core
Abstract:	The present invention is directed to methods and compositions for blocking the effect of the intronic inhibitory splicing region of intron 7 of the SMN2 gene. The compositions and methods of the instant invention include short oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target sites in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The short target regions are 8-mers and 5-mers and also include the identification of a single nucleotide base that is essential for initiating a long distance stearic inhibitory interactions as well as novel targets distant from intron 7 which block the intronic inhibitory splicing of the same. These short target regions and concomitant inhibitory blocking oligonucleotides are less expensive and easier to manufacture and are small enough to cross the blood brain barrier.
Inventor(s):	Singh; Ravindra N. (Ames, IA), Singh; Natalia N. (Ames, IA)
Assignee:	Iowa State Research Foundation, Inc. (Ames, IA)
Application Number:	14/134,057
Patent Claims:	1. A method of enhancing the level of exon 7-containing SMN2 mRNA relative to exon-deleted SMN2 mRNA in a cell or cell extract, comprising contacting the cell or cell extract with an oligonucleotide of 8 to 19 nucleotides in length which is complementary to at least 8 contiguous nucleotides of CUGCCAGCAUUAUGAAAG (nucleotides 7 to 24 of SEQ ID NO: 2) of intron 7 of the SMN2 gene, wherein said oligonucleotide is complementary to nucleotide 10 (.sup.10C) and; said oligonucleotide is 8 to 14 nucleotides in length and is complementary to nucleotides 7, 8, and 9 of intron 7 of the SMN2 gene; or said oligonucleotide is 8 to 14 nucleotides in length and is complementary to nucleotides 8 and 9 of intron 7 of the SMN2 gene; or said oligonucleotide is 11, 13, 14, 16, 17, or 19 nucleotides in length and is complementary to none of nucleotides 7, 8, and 9; or said oligonucleotide is 11 to 14 nucleotides in length and is complementary to nucleotide 9 of intron 7 of the SMN2 gene; such that the level of exon 7-containing SMN2 mRNA relative to exon-deleted SMN2 mRNA in the cell or cell extract is enhanced. 2. The method of claim 1, wherein said oligonucleotide has a sequence complementary to the sequence 5'-CUGCCAGC-3'. 3. The method of claim 1, wherein said oligonucleotide has a sequence complementary to the sequence 5'-CUGCC-3'. 4. The method of claim 1, wherein the cell or cell extract is a spinal muscular atrophy (SMA) patient-derived neuronal cell, muscle cell or fibroblast, or extract thereof. 5. The method of claim 1, wherein the cell or cell extract is selected from the group consisting of an embryonic stem cell, an embryonic stem cell extract, a neuronal stem cell and a neuronal stem cell extract. 6. The method of claim 1, wherein the oligonucleotide is modified by the substitution of at least one nucleotide with a modified nucleotide, such that in vivo stability is enhanced as compared to a corresponding unmodified oligonucleotide. 7. The method of claim 6, wherein the modified nucleotide is a sugar-modified nucleotide. 8. The method of claim 6, wherein the modified nucleotide is a nucleobase-modified nucleotide. 9. The method of claim 8, wherein the modified nucleotide is a 2'-deoxy ribonucleotide. 10. The method of claim 9, wherein the 2'-deoxy ribonucleotide is 2'-deoxy adenosine or 2'-deoxy guanosine. 11. The method of claim 6, wherein the modified nucleotide is a 2-O-methyl ribonucleotide. 12. The method of claim 6, wherein the modified nucleotide is selected from the group consisting of a 2'-fluoro, 2'-amino and 2'-thio modified ribonucleotide. 13. The method of claim 6, wherein the modified nucleotide is selected from the group consisting of 2'-fluoro-cytidine, 2'-fluoro-uridine, 2'-fluoro-adenosine, 2'-fluoro-guanosine, 2'-amino-cytidine, 2'-amino-uridine, 2'-amino-adenosine, 2'-amino-guanosine and 2'-amino-butyryl-pyrene-uridine. 14. The method of claim 6, wherein the modified nucleotide is selected from the group consisting of 5-bromo-uridine, 5-iodo-uridine, 5-methyl-cytidine, ribo-thymidine, 2-aminopurine, 5-fluoro-cytidine, and 5-fluoro-uridine, 2,6-diaminopurine, 4-thio-uridine, and 5-amino-allyl-uridine. 15. The method of claim 6, wherein the modified nucleotide is a backbone-modified nucleotide. 16. The method of claim 15, wherein the backbone-modified nucleotide contains a phosphorothioate group. 17. The method of claim 6, wherein the modified nucleotide is a locked nucleic acid (LNA). 18. A method of enhancing the level of exon 7-containing SMN2 mRNA relative to exon-deleted SMN2 mRNA in an organism, comprising administering to the same an oligonucleotide of 8 to 19 nucleotides in length which is complementary to 8 consecutive nucleotides of nucleotides 7 to 24 (CUGCCAGCAUUAUGAAAG) of, wherein said oligonucleotide is complementary to nucleotide 10 (.sup.10C) of intron 7 of the SMN2 gene and: said oligonucleotide is 8 to 14 nucleotides length and is complementary to nucleotides 7, 8, and 9 of intron 7 of the SMN2 gene; or said oligonucleotide is 8 to 14 nucleotides in length and is complementary to nucleotides 8 and 9 of intron of the SMN2 gene; or said oligonucleotide is 11, 13, 14, 16, 17, or 19 nucleotides in length and is complementary to none of nucleotide 7, 8, and 9; or said oligonucleotide is 11 to 14 nucleotides in length and is complementary to nucleotide 9 of intron 7 of the SMN2 gene, such that the level of exon 7-containing SMN2 mRNA relative to exon-deleted SMN2 mRNA in the organism extract is enhanced. 19. The method of claim 18, wherein the organism is a mammal. 20. The method of claim 19, wherein the organism is a human. 21. The method of claim 20, wherein the human has spinal muscular atrophy (SMA). 22. The method of claim 18, wherein said oligonucleotide has a sequence complementary to the sequence 5'-CUGCCAGC-3'. 23. The method of claim 18, wherein said oligonucleotide has a sequence complementary to the sequence 5'-CUGCC-3'. 24. A method of treating spinal muscular atrophy (SMA) in a patient, comprising administering to the patient an oligonucleotide of 8 to 19 nucleotides m length, which is complementary to at least 8 contiguous nucleotides of CUGCCAGCAUUAUGAAAG (nucleotides 7 to 24 of SEQ ID NO: 2) of intron 7 of the SMN2 gene, wherein said oligonucleotide is complementary to nucleotide 10 (.sup.10C) of intron 7 Of the SMN2 gene and; said oligonucleotide is 8 to 14 nucleotides m length and is complementary to nucleotides 7, 8, and 9 of intron 7 of the SMN2 gene; or said oligonucleotide is 8 to 14 nucleotides in length and is complementary to nucleotides 8 and 9 of intron 7 of the SMN2 gene; or said oligonucleotide is 11, 13, 14, 16, 17, or 19 nucleotides in length and is complementary to none of nucleotides 7, 8, and 9; or said oligonucleotide is 11 to 14 nucleotides in length and is complementary to nucleotide 9 of intron 7 of the SMN2 gene, said oligonucleotide being administered in an amount effective to enhance the level of exon 7-containing SMN2 mRNA relative to exon-deleted SMN2 mRNA in cells of the patient, such that SMA in the patient is treated. 25. The method of claim 24, wherein said oligonucleotide has a sequence complementary to the sequence 5'-CUGCCAGC-3'. 26. The method of claim 24, wherein said oligonucleotide has a sequence complementary to the sequence 5'-CUGCC-3'.

Details for Patent 9,217,147

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2030-04-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2030-04-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2030-04-28